Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01413178 · ClinicalTrials.gov registry record · Phase 3
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
NCT01413178: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT01413178 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 205 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01413178, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to compare Busulfex (busulfan) with or without Alkeran (melphalan) to learn which study therapy may be better at helping to control MM in patients who will receive an autologous stem cell transplant. The safety of this combination therapy will also be studied. Melphalan and busulfan are designed to damage the DNA (genetic material) of cells, which may cause cancer cells to die.
Interventions
- DRUG Melphalan
- DRUG Busulfan
- DRUG G-CSF
- OTHER Questionnaire
- DRUG High Dose Melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2011-09-30 |
| Est. Completion | 2019-03-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01413178
The ClinicalTrials.gov registry entry for NCT01413178 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT01413178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01413178 about?
NCT01413178 is a clinical study titled "A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma". The goal of this clinical research study is to compare Busulfex (busulfan) with or without Alkeran (melphalan) to learn which study therapy may be better at helping to control MM in patients who will receive an autologous stem cell transplant. The safety of this combination therapy will also be stud...
What is the current status of trial NCT01413178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2011-09-30. Estimated completion is 2019-03-10.
What interventions are being tested in trial NCT01413178?
The interventions under investigation include: Melphalan (DRUG), Busulfan (DRUG), G-CSF (DRUG), Questionnaire (OTHER), High Dose Melphalan (DRUG).
Who is sponsoring clinical trial NCT01413178?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.